Severe CIDP-MGUS responsive to Rituximab.
Anatomy
B-cell dyscrasia
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Musculoskeletal system
Nerve Conduction Sudies (NCS)
Nervous system
Neurology
Physiology
Rituximab
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
11
04
2020
revised:
26
05
2020
accepted:
12
06
2020
entrez:
30
6
2020
pubmed:
1
7
2020
medline:
1
7
2020
Statut:
epublish
Résumé
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a relatively rare disease with progressive limb weakness and sensory loss. A few patients show a severely progressing course without major response to intravenous immunoglobulin or plasma exchange therapy. CIDP-MGUS (monoclonal gammopathy of undetermined significance) is a seldom CIDP variant that has been rarely addressed in therapeutic studies. In the presented CIDP-MGUS case, B cell depletion with rituximab had a favourable effect on the disease course, clinically and in nerve conduction studies.
Identifiants
pubmed: 32596526
doi: 10.1016/j.heliyon.2020.e04230
pii: S2405-8440(20)31074-4
pii: e04230
pmc: PMC7306592
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e04230Informations de copyright
© 2020 The Authors. Published by Elsevier Ltd.
Références
J Neurol Neurosurg Psychiatry. 2015 Sep;86(9):973-85
pubmed: 25677463
J Anat. 2002 Apr;200(4):331-9
pubmed: 12090400
Muscle Nerve. 2006 Apr;33(4):575-80
pubmed: 16323216
Neuroepidemiology. 2019;52(3-4):161-172
pubmed: 30669140
Eur J Neurol. 2010 Mar;17(3):356-63
pubmed: 20456730
J Neurol Neurosurg Psychiatry. 2011 Mar;82(3):306-8
pubmed: 20639381
Cochrane Database Syst Rev. 2017 Nov 29;11:CD002062
pubmed: 29185258